ScreenerHero

ALDXAldeyra Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · aldeyra.com
1.520USD-3.80%Mkt Cap: 91.70M $P/E: —

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, wh…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0
HeadlineSourceTime
Older
CEO, President & Director of Aldeyra Therapeutics Picks Up 18% More Stock
Simply Wall St.
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment
MarketBeat
3 Promising Penny Stocks With Market Caps Reaching $300M
Simply Wall St.
Upstart Holdings Leads These 3 Stocks Estimated To Be Trading Below Fair Value

Over the last 7 days, the United States market has risen by 1.1%, and over the past 12 months, it is up by an impressive 27%, with earnings expected to grow by 17% per annum in the coming years. In this context of robust market performance, identifying stocks that are trading below their fair value can be a strategic move for investors seeking opportunities for potential growth and value.

Simply Wall St.
3 Stocks That May Be Undervalued According To Analysts In May 2026

Over the last 7 days, the United States market has risen by 1.1%, contributing to a remarkable 27% climb over the past year, with earnings forecasted to grow by 17% annually. In this thriving environment, identifying stocks that may be undervalued can present opportunities for investors seeking potential value plays amidst strong market performance.

Simply Wall St.
Pleasing Signs As A Number Of Insiders Buy Aldeyra Therapeutics Stock

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

Simply Wall St.
Extreme Networks And 2 Additional Stocks Estimated To Be Trading Below Their Fair Value

In the last week, the United States market has stayed flat, yet it is up 29% over the past year with earnings forecasted to grow by 16% annually. In such a climate, identifying stocks that are potentially undervalued can present opportunities for investors looking to capitalize on discrepancies between stock prices and their intrinsic values.

Simply Wall St.
Discover 3 Stocks That Might Be Trading Below Estimated Value

In the last week, the United States market has stayed flat, although it is up 29% over the past year with earnings forecasted to grow by 16% annually. In such a climate, identifying stocks that might be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on future growth.

Simply Wall St.
3 Stocks Estimated To Be Trading Below Intrinsic Value By Up To 35.4%

The United States market has remained flat over the last week but has seen a significant rise of 29% over the past 12 months, with earnings forecasted to grow by 16% annually. In this context, identifying stocks that are trading below their intrinsic value can present compelling opportunities for investors seeking to capitalize on potential growth while navigating current market conditions.

Simply Wall St.
3 Stocks That May Be Trading Below Their Estimated Value In April 2026

Over the last 7 days, the United States market has remained flat, yet over the past 12 months, it has risen by an impressive 29%, with earnings forecasted to grow by 16% annually. In these conditions, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on future growth.

Simply Wall St.